Shares of MannKind Corp.
MNKD,
fell 1.5% premarket on Monday after the biopharma company said a fire at a German manufacturing facility may delay the planned initiation later this year of a phase 2/3 clinical study of MNKD-101, a treatment for nontuberculous myobacterial lung disease. The facility was producing clofazimine inhalation solution, the investigational product that MannKind is developing as MNKD-101, MannKind said in a Securities and Exchange Commission filing Monday. Clinical supplies of MNKD-101 will be delayed an estimated three to six months, according to the filing. The company is “evaluating several mitigation strategies and will update the projected timing for this clinical study at a later date,” the filing said.
